Skip to content
Bacil Pharma logo

Bacil Pharma

524516 BSE
₹17.45

Close ·

P/E
37.93
View as Markdown
MCP
Close 4 Nov 2026 ₹17.45 −12.19 −41.1% 1Y
Start ₹29.64

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare

Price-based figures at the close · EPS basis: Consolidated · TTM

ROCE
3.93%
Debt to Equity
0.00
EPS (TTM)
₹0.46
Book Value
₹17.55
Market Cap
—
P/E (TTM)
37.93
P/B
0.99
ROE
6.21%
Dividend Yield
0.00%
EBITDA
₹1.00 Cr
52W High
₹61.80
52W Low
₹10.65

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

43 Weak

Data confidence 89/100

Category scores

Quality
49
Average
Returns, margins, earnings quality 24% weight
Valuation
38
Weak
Cheap vs sector & own history 26% weight
Financial Health
65
Good
Solvency, leverage, coverage 10% weight
Momentum
3
Poor
Trend strength, vol-adjusted 13% weight
Ownership
50
Average
FII/DII/promoter flows 26% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

2
  • Company has reduced debt.
  • Company is almost debt free.

Weaknesses

2
  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 3.18% over last 3 years.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1234
OscillatorsBullish234
Moving AveragesStrong Bearish1000

Key readings

RSI (14)
31.34
Neutral
MACD (12,26,9)
−1.16
Bearish
SMA (50)
20.04
Bearish
SMA (200)
37.20
Bearish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10YZero base
5YZero base
3YZero base
1YZero base
TTMZero base

Net profit

Net profit growth by window
10YTurned to profit
5YTurned to profit
3YTurned to profit
1Y+290.00%
TTM−41.44%

Operating cash flow

Operating cash flow growth by window
10Y+28.03%
5YTurned positive
3YTurned positive
1Y+77.50%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10YNo sales
5YNo sales
3YNo sales
1YNo sales
TTMNo sales

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018₹0.00 Cr
Mar 2019₹0.00 Cr
Mar 2020₹0.00 Cr
Mar 2021₹0.00 Cr
Mar 2022₹0.00 Cr
Mar 2023₹0.00 Cr
Mar 2024₹0.00 Cr
Mar 2025₹0.00 Cr
Mar 2026₹0.00 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017₹0.00 Cr
Mar 2018−₹3.75 Cr
Mar 2019−₹0.34 Cr
Mar 2020−₹0.32 Cr
Mar 2021−₹0.24 Cr
Mar 2022−₹3.86 Cr
Mar 2023−₹0.10 Cr
Mar 2024−₹0.06 Cr
Mar 2025₹0.40 Cr
Mar 2026₹1.56 Cr

Quarterly Results

₹ Cr
524516 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0.03
0.04
0.05
0.06
0.04
0.07
0.06
0.07
0.11
0.03
0.02
0.07
0.02
Operating Profit
−0.03
−0.04
−0.05
−0.06
−0.04
−0.07
−0.06
−0.07
−0.11
−0.03
−0.02
−0.07
−0.02
Other Income
0.05
0.03
0.03
0.02
0.01
0.56
0
0.09
1
0.05
0.06
0.11
0.09
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.02
−0.01
−0.02
−0.04
−0.03
0.49
−0.06
0.02
0.89
0.02
0.04
0.04
0.07
Tax %
0%
0%
0%
0%
0%
0%
0%
0%
24.72%
0%
0%
−1450%
114.29%
Net Profit
0.02
−0.01
−0.02
−0.04
−0.03
0.48
−0.06
0.02
0.67
0.01
0.04
0.62
−0.02
EPS (₹)
0.03
−0.02
−0.03
−0.07
−0.05
0.81
−0.1
0.01
0.47
0.01
0.03
0.43
−0.01

Profit & Loss

₹ Cr
524516 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
0
0
0
0
0
0
0
0
0
0
0
0
0
Expenses
0.11
0.13
0.17
0.29
0.26
0.18
0.16
0.16
0.17
0.19
0.25
0.25
0.14
Operating Profit
−0.11
−0.13
−0.17
−0.29
−0.26
−0.18
−0.16
−0.16
−0.17
−0.19
−0.25
−0.25
−0.14
Other Income
0.08
0.06
0.17
−3.42
−0.07
−0.12
−0.07
−3.7
0.07
0.13
0.66
1.24
0.31
Interest
0
0
0
0.03
0
0.01
0
0
0
0
0
0
0
Depreciation
0
0
0
0.01
0.01
0.01
0
0
0
0
0
0
0
PBT
−0.03
−0.07
0
−3.75
−0.34
−0.32
−0.23
−3.86
−0.1
−0.06
0.41
0.99
0.17
Tax %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
−57.58%
—
Net Profit
−0.03
−0.07
0
−3.75
−0.34
−0.32
−0.24
−3.86
−0.1
−0.06
0.4
1.56
0.65
EPS (₹)
−0.05
−0.12
0
−6.37
−0.58
−0.54
−0.41
−6.55
−0.17
−0.1
0.28
1.09
0.46
Div. Payout %
0%
0%
—
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
524516 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
6.53
6.53
6.53
6.53
6.53
6.53
6.53
6.53
6.53
6.53
13.97
13.97
Reserves
−0.06
−0.13
−0.09
−4.29
−4.62
−5.14
−5.14
−5.3
−5.43
−5.31
11.46
10.84
Borrowings
0.14
0.27
0.31
0
0.1
0.17
0.18
0.03
0.02
0.1
0.16
0
Other Liabilities
0.02
0.02
0.02
2.51
2.55
2.55
2.52
0.01
0.01
0.01
0.02
2.58
Total Liabilities
6.63
6.69
6.77
4.75
4.56
4.11
4.09
1.27
1.13
1.33
25.61
27.39
Fixed Assets
0.01
5.25
5.94
2.53
2.53
2.52
2.51
0.01
0.01
0.01
0
0
CWIP
5.88
0
0
0
0
0
0
0
0
0
0
0
Investments
0.51
0.51
0.54
1.15
0.96
0.43
0.37
0.31
0.43
0.61
21.36
24.24
Other Assets
0.23
0.93
0.29
1.07
1.07
1.16
1.21
0.95
0.69
0.71
4.25
3.15
Total Assets
6.63
6.69
6.77
4.75
4.56
4.11
4.09
1.27
1.13
1.33
25.61
27.39

Cash Flow

₹ Cr
524516 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
0.26
0.06
0
1.44
−0.3
−0.38
−0.4
−4.01
−0.15
0
0.4
0.71
Investing
−0.33
−0.05
0.02
−1.2
0.28
0.39
0.53
3.81
−0.12
0.08
0.34
−2.38
Financing
0
0
0
0
−0.16
−0.06
−0.07
0.33
0.06
−0.06
2.08
−0.62
Net Cash Flow
−0.07
0.01
0.02
0.23
−0.18
−0.05
0.06
0.13
−0.2
0.01
2.82
−2.29
Free Cash Flow
0.24
−3.21
0
1.14
−0.3
−0.38
−0.4
−4.01
−0.15
0
0.4
0.71
CFO/OP
−236
−46
0
−497
115
211
250
2,506
88
0
−160
−284

Ratios

524516 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
ROCE %
−0.45%
−1.05%
−1.49%
−6.01%
−8.47%
−2.8%
−5.75%
−7.07%
−12.61%
−13.11%
−0.97%
3.93%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bacil Pharma insights

49 extracted metrics across FY10–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 85.39%
  • Others 14.61%

No promoter shares pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Bacil Pharma

What does Bacil Pharma Ltd do?
Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities.
Where is Bacil Pharma Ltd (BACPHAR) listed?
Bacil Pharma Ltd trades under code 524516 on the BSE.
Which sector does Bacil Pharma Ltd belong to?
Bacil Pharma Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the PE ratio of Bacil Pharma Ltd?
Bacil Pharma Ltd trades at a PE ratio of 37.93 as of 4 Nov 2026, on earnings per share of ₹0.46, against a book value of ₹17.55 per share.
What is the 52-week high and low of Bacil Pharma Ltd?
Over the last 52 weeks Bacil Pharma Ltd has traded between ₹10.65 and ₹61.8 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Bacil Pharma Ltd?
Bacil Pharma Ltd reported a return on equity of 6.21%. Its debt-to-equity ratio is 0.00.

Company Information

Bacil Pharma Limited is a Mumbai-registered listed company incorporated in 1987. Although its stated business is pharmaceutical healthcare, it recorded no core operating revenue in FY26 and is currently an investment/other-income-led, non-operating company evaluating future business opportunities.

Website bacilpharma.com
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/524516.md for Bacil Pharma Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month